Ακτινοθεραπεία στον καρκίνο μαστού σταδίου T1-2NO-1MO με επιταχυνόμενο σχήμα υποκερματισμού δόσης: έλεγχος ανταπόκρισης και εκτίμηση άμεσης και όψιμης τοξικότητας

Abstract

In the present study participated 54 patients (mean age 56 ± 9). 39 of 54 patients (72,2%), had tumors with volume between 0-1.9 cm and 15 of 54 patients (27,8%) had tumors with volume between 2-4,9 cm. 44 patients (81,5%), had positive lymph nodes and 10 (18,5%) had negative lymph nodes. By the end of the therapy it was observed that 36 patients (66,7%) had side effects grade 0, 13 patients (24,1%) had side effects grade 1 and 5 patients (9,3%) had side effects grade 2. One month after the end of the therapy it was observed that 42 patients (77,8%) had side effects grade 0, 7 patients (13,0%) had side effects grade 1, 4 patients (7,4%) had side effects grade 2 and 1 patient (1,9%) had side effects grade 3. Two months after the end of the therapy it was observed that 48 patients (88,9%) had side effects grade 0, 5 patients (9,3%) had side effects grade 1, 1 patient (1,9%) had side effects grade 2. Three months after the end of the therapy it was observed that 49 patients (90,7%) had side effects grade 0 and 5 patients (9,3%) had side effects grade 1. Six months after the end of the therapy it was observed that 49 patients (90,7%) had side effects grade 0 and 5 patients (9,3%) had side effects grade 1. Twelve months after the end of the therapy it was observed that 52 patients (96,3%) had side effects grade 0 and 2 patients (3,7%) had side effects grade 1. Eighteen months after the end of the therapy it was observed that 53 patients (98,1%) had side effects grade 0 and 1 patient (1,9%) had side effects grade 1. Twenty four months after the end of the therapy it was observed that all of the 54 patients (100,0%) had side effects grade 0. Kaplan-Meier analysis showed that 50% of the patients had no side effects by the end of the therapy (total relapse of breast to normal condition) and that 75% of the patients relapsed one month after the end of the therapy. Statistical analysis of the correlation between the kind of the therapy and the grade, revealed no significant results. Next mammography findings were evaluated. Six months after the end of the therapy it was observed that 6 patients (11,1%) had thickening of trabecula 0, 18 patients (33,3%) had thickening of trabecula 1, 20 patients (37,0%) had thickening of trabecula 2 and 10 patients (18,5%) had thickening of trabecula 3. Twelve months after the end of the therapy it was observed that 22 patients (40,7%) had thickening of trabecula 0, 21 patients (38,9%) had thickening of trabecula 1 and 11 patients (20,4%) had thickening of trabecula 2. Twenty four months after the end of the therapy it was observed that 47 patients (87,0%) had thickening of trabecula 0 and 7 patients (13%) had βαθμό επίτασης δοκίδωσης 1. Patients distribution according to skin thickening was the following: Six months after the end of the therapy it was observed that 8 patients (14,8%) had grade 0, 23 patients (42,6%) had grade 1, 17 patients (31,5%) had grade 2 and 6 patients (11,1%) had grade 3. Twelve months after the end of the therapy it was observed that 26 patients (48,1%) had grade 0, 21 patients (38,9%) had grade 1, 6 patients (11,1%) had grade 2 and 1 patient (1,9%) had grade 3. Twenty four months after the end of the therapy it was observed that 43 patients (79,6%) had grade 0, 10 patients (18,5%) had grade 1 and 1 patient (1,9%) had grade 2. ..........................................................